肿瘤患者的骨痛与骨转移分析

目的　分析骨痛与肿瘤骨转移的关系 ,并探讨骨转移骨痛的可能机理。方法　对 2 5 2例主诉骨痛的肿瘤患者的骨显像结果与其骨痛部位、数目及发生时间进行分析。结果　①有骨痛的各类型肿瘤患者骨转移率平均为64 .7%,其中以前列腺癌为最高 ;骨转移阴性和阳性患者平均骨痛部位数目分别为 1.0 5和 1.73个 ;主诉骨盆骨痛的患者骨转移率最高 ,达到 10 0 %;②骨痛出现的病程时间相对集中在半年至 5年 ,各时间段均可发生转移 ;骨转移病灶数平均为 7.5 7个 ,有随时间段的后移而增加的趋势。结论　①有骨痛主诉时 ,患者骨转移率已高达 64 .7%,而且常为多灶转移 ,已基本失去肿瘤骨转移的早期治疗机会。②对高发骨转移的肿瘤患者应及早进行骨显像检查 ,同时 ,要根据不同类型的肿瘤骨转移特点 ,确定适宜的骨显像随访期 ,这对于肿瘤治疗方案的确定及疗效评估、预后判定均有重要意义

Analysis on the relation between bone pain and bone metastases in patients with malignancy

Objective To investigate the relationship between bone pain and bone metastases and study the possible mechanism of this bone pain in patients with malignancy. Methods It's analyzed that the bone scan resultsof 252 patients with malignancy who have bone pain, and where, how many, when their bone pain arise. Results ① The average positive rate of bone metastases in the patients with malignancy who have bone pain was 64.7%. Among these, the highest is prostatic cancer; The average position of the bone pain in negative patients is 1.05, other hand the positive is 1.73; The rate of the patients who havethe bone pain of pelvis reach 100%. ② The time when bone pain happen comparatively concentrate during half a year to five years during thecourse of disease, bone metastases can arise in any stage; The average number of bone metastases is 7.57, which had a drift of increase with time. Conclusion ① When the patients have bone pain, the incidence rate bone metastases has been up to 64.7%, majority are pluri-metastases, it have lost the chance of early stage treatment which aimed at the bone metastases. ② For the patients with malignancy who have a higher risk of bone metastases, bone scan should be performed as soon as possible. Furthermore, according to the characteristics of bonemetastases in the various types of malignant tumor, the right time that these patients follow up with bone scan can be determined. That is helpful for laying down a plan of treatment, estimation of therapeutic efficiency and predicting prognosis of malignant tumor.